DHDaniel Hain

Daniel Hain

*This is an algorithmically generated author record based on publicly available information.

Daniel Hain has a total of 55 co-authors. Here are the top co-authors by number of shared publications:

  • Boadie W. Dunlop

    Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA 30329, United States

    2 shared publications
  • Brent P. Forester

    McLean Hospital, Division of Geriatric Psychiatry, Belmont, MA 02478, United States; Harvard Medical School, Boston, MA, United States

    2 shared publications
  • Charles DeBattista

    Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA 94305, United States

    2 shared publications
  • Charles R. Conway

    Department of Psychiatry, Washington University School of Medicine, and the John Cochran Veteran's Administration Hospital, St. Louis, MO 63110, United States

    2 shared publications
  • David J. Lewis

    Myriad Neurosci, Mason, OH 45040 USA

    2 shared publications
  • Holly L. Johnson

    Myriad Genetics, Inc., Salt Lake City, UT

    2 shared publications

Latest Publications

  • Open Access

    Meta-analysis of Response and Remission Outcomes With a Weighted Multigene Pharmacogenomic Test for Adults With Depression

    by Renee E. Albers, Melissa P. Dyer, Matthew Kucera, Daniel Hain, Alexander Gutin, Andria L. Del Tredici, Rachael H. Earls, Sagar V. Parikh, Holly L. Johnson, Rebecca Law, et al.

    Purpose/Background: Multiple meta-analyses have suggested that pharmacogenomic (PGx) testing may be a valuable tool to improve clinical outcomes for patients with major depressive disorder (MDD) who have failed at least one treatment. However, these meta-analyses included studies with different PGx tests and different trial designs, which produce uncertainty when interpreting results. To investigate the clinical utility of a single weighted multigene PGx test, a meta-analysis was performed for prospective studies utilizing this PGx test in adult patients with MDD. Methods/Procedures: MEDLINE/PubMed and Cochrane [including Embase, clinicaltrials.gov, and International Clinical Trials Registry Platform (ICTRP)] were searched through May 2025 for studies evaluating the impact of pharmacogenomic testing on outcomes for patients with MDD. Using PRISMA guidelines, 243 records were identified, and 6 studies were included that compared PGx-guided care to unguided care in adult patients with MDD, using a single weighted multigene test. Findings/Results: Overall, 3,532 patients were included, with outcomes evaluated at week 8 or week 10. Patients with MDD whose care was guided by the weighted multigene PGx test were 30% more likely to achieve response [relative risk ratio (RR)=1.30, 95% CI: 1.16-1.47, P P <0.001] compared to unguided care. No heterogeneity in outcomes across studies was detected. Implications/Conclusions: Prescribing informed by a weighted multigene PGx test significantly improved response and remission rates among adult patients with MDD who experienced at least 1 prior treatment failure, further demonstrating the clinical utility of weighted multigene PGx testing.


  • Elevated Matrix Metalloproteinase 9 in Treatment Resistant Bipolar Depression

    by Evangelia Fatourou, Alexander Truong, Debra Hoppensteadt, Jawed Fareed, Daniel Hai̇n, James Si̇nacore, Angelos Halari̇s

    Objective: Matrix metalloproteinase is a family of proteases with different pathophysiological roles. Matrix metalloproteinase 9 (MMP9) plays an enzymatic role in the restructuring of the extracellular matrix and adhesion molecules. MMP9 is upregulated in pro-inflammatory states and leads to breakdown of tight junctions thereby increasing blood-brain barrier (BBB) permeability. MMP9 may contribute to the pathophysiology of bipolar disorder (BD) via proteolysis of the BBB thus allowing entry of cytokines and neurotoxic agents into CNS. Polymorphisms of the MMP9 gene may pose increased risk for BD and schizophrenia. In this study we sought to determine MMP9 levels in treatment resistant bipolar depressed patients before and after treatment. Methods: Treatment resistant bipolar depressed patients were treated with escitalopram, in combination with the COX-2 inhibitor, celecoxib. It was hypothesized that combination treatment would reverse resistance and augmented treatment responses. This was a 10-week, randomized, double-blind, two-arm, placebo-controlled study. Results: MMP9 levels were higher in bipolar depressed patients compared to healthy controls at baseline, however, the difference did not reach significance. Levels decreased after treatment reaching significance in the escitalopram plus placebo group. Female patients had significantly lower MMP9 levels at end of treatment. MMP9 was higher in carriers the MMP9 SNP, rs3918242, than in noncarriers, but the difference did not reach statistical significance. Conclusion: MMP9 decreased in bipolar depressed patients with treatment. Age, sex and the rs3918242 polymorphism play a role in MMP9 levels. Future studies should confirm the role of MMP9 in the pathogenesis and pathophysiology of bipolar disorder, as a potential diagnostic biomarker.

  • Open Access

    Pharmacogenomic Profiling of Pediatric Patients on Psychotropic Medications in an Emergency Department

    by Pallavi Ghosh, Jesse Martinez, Nipam Mbbs Shah, Will Kenan, Andrew Fowler, Nita PharmD Limdi, Lindsey Mba Burns, Elizabeth S. Cogan, Anna Gardiner, Daniel Bs Hain, et al.

    Objective: The aim of the study was to evaluate the ability of a combinatorial pharmacogenomic test to predict medication blood levels and relative clinical improvements in a selected pediatric population. Methods: This study enrolled patients between ages 3 to 18 years who presented to a pediatric emergency department with acute psychiatric, behavioral, or mental health crisis and/or concerns, and had previously been prescribed psychotropic medications. Patients received combinatorial pharmacogenomic testing with medications categorized according to gene-drug interactions (GDIs); medications with a GDI were considered “incongruent,” and medications without a GDI were considered “congruent.” Blood levels for escitalopram, fluoxetine, aripiprazole, and clonidine were evaluated according to level of GDI. Relative clinical improvements in response to the prescribed psychotropic medications were measured using a parent-rated Clinical Global Impression of Improvement (CGI-I) assessment, where lower scores corresponded with greater improvement. Results: Of the 100 patients enrolled, 73% reported taking ≥1 incongruent medication. There was no significant difference in CGI-I scores between patients prescribed congruent versus incongruent medications (3.37 vs 3.68, P = 0.343). Among patients who presented for depression or suicidal ideation, those prescribed congruent medications had significantly lower CGI-I scores compared with those taking incongruent medications (P = 0.036 for depression, P = 0.018 for suicidal ideation). There was a significant association between medication GDI and blood levels for aripiprazole (n = 15, P = 0.01) and escitalopram (n = 10, P = 0.01). Conclusions: Our preliminary findings suggest that combinatorial pharmacogenomic testing can predict medication blood levels and relative outcomes based on medication congruency in children presenting to an emergency department with acute psychiatric/behavioral crises. Additional studies will be needed to confirm these findings.


  • Open Access

    Pharmacogenomics of Clozapine-induced agranulocytosis: a systematic review and meta-analysis

    by Farhana Islam, Daniel Hain, David Lewis, Rebecca Law, Lisa C. Brown, Julie-Anne Tanner, Daniel J. Müller

    Although clozapine is the most effective pharmacotherapy for treatment-resistant schizophrenia, it is under-utilized, and initiation is often delayed. One reason is the occurrence of a potentially fatal adverse reaction, clozapine-induced agranulocytosis (CIA). Identifying genetic variations contributing to CIA would help predict patient risk of developing CIA and personalize treatment. Here, we (1) review existing pharmacogenomic studies of CIA, and (2) conduct meta-analyses to identify targets for clinical implementation. A systematic literature search identified studies that included individuals receiving clozapine who developed CIA and controls who did not. Results showed that individuals carrying the HLA-DRB1*04:02 allele had nearly sixfold (95% CI 2.20–15.80, pcorrected = 0.03) higher odds of CIA with a negative predictive value of 99.3%. Previously unreplicated alleles, TNFb5, HLA-B*59:01, TNFb4, and TNFd3 showed significant associations with CIA after multiple-testing corrections. Our findings suggest that a predictive HLA-DRB1*04:02-based pharmacogenomic test may be promising for clinical implementation but requires further investigation.


  • Open Access

    Review and Meta-analysis on the Impact of the ADRA2A Variant rs1800544 on Methylphenidate Outcomes in Attention-Deficit/Hyperactivity Disorder

    by Daniel T. Hain, Talal Al Habbab, Elizabeth S. Cogan, Holly L. Johnson, Rebecca A. Law, David J. Lewis


  • Open Access

    Clinical validation of combinatorial pharmacogenomic testing and single-gene guidelines in predicting psychotropic medication blood levels and clinical outcomes in patients with depression

    by Anthony J. Rothschild, Sagar V. Parikh, Daniel Hain, Rebecca Law, Michael E. Thase, Boadie W. Dunlop, Charles DeBattista, Charles R. Conway, Brent P. Forester, Richard C. Shelton, et al.


  • Open Access

    Combinatorial Pharmacogenomic Algorithm is Predictive of Citalopram and Escitalopram Metabolism in Patients with Major Depressive Disorder

    by Richard C. Shelton, Sagar V. Parikh, Rebecca A. Law, Anthony J. Rothschild, Michael E. Thase, Boadie W. Dunlop, Charles DeBattista, Charles R. Conway, Brent P. Forester, Matthew Macaluso, et al.